X4 Pharmaceuticals, Inc: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 13, 2024 and accepted by EDGAR at Nov 13, 2024, 09:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $227.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $495.0k | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $19.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-01-01 to 2024-09-30 | $59.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$34.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | −$686.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-07-01 to 2024-09-30 | $2.4m | us-gaap:InterestExpense |
| Interest expense | 9 months2024-01-01 to 2024-09-30 | $6.5m | us-gaap:InterestExpense |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $15.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-30 | $52.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$36.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | $2.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$0.18 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.18 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 200,865,276 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 200,611,232 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | −$97.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-01-01 to 2024-09-30 | $285.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2024-09-30 | $97.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $143.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $178.2m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $29.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $118.5m | us-gaap:Liabilities |
| Long-term debt | At period end2024-09-30 | $75.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2024-09-30 | $59.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-047445. Last ingested by Listed: Oct 29, 2026, 10:01 ET. Listed shows no prices and gives no investment advice.